← Back to Clinical Trials
Recruiting NCT07149571

To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Nonalcoholic Fatty Liver Disease
Sponsor Tongji Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 500
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2025-04-01
Completion 2032-12-01

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to explore the value of new MR technology in assessing the systemic metabolism, disease status, and prognostic risk of metabolism-related fatty liver disease. By obtaining clinical, imaging, laboratory examination and pathological data of metabolism-related fatty liver disease, image processing software is used to analyze the images, explore the relationship between imaging parameters, body composition and metabolic diseases and metabolism-related fatty liver disease, and achieve non-invasive diagnosis, efficacy evaluation, and prognosis prediction of metabolism-related fatty liver disease. Thereby guiding clinical treatment and improving the prognosis and quality of life of patients with metabolism-related fatty liver disease

Eligibility Criteria

Inclusion Criteria: 1. Patients with MR examination are clinically suspected or diagnosed with metabolism-related fatty liver disease; 2. Age/gender: unlimited; 3. Patients who voluntarily participate in clinical trials and sign written subject informed consent Exclusion Criteria: 1. Clinical suspicion or diagnosis of metabolism-related fatty liver disease and having been prescribed an MR examination; 2. Voluntarily participation in the study and provision of written informed consent.

Related Trials

}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology